Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26240876 | 0.94 | MGLL (0.39) | MGLLPIK3CDPDCD1LG2CD274CYP2D6 | |
| SCHEMBL20021314 | 0.90 | MGLL (0.43) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL25044979 | 0.87 | MGLL (0.49) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL3422922 | 0.83 | KCNH2 (0.42) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP2C9 | |
| SCHEMBL26240870 | 0.81 | MGLL (0.53) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL27283086 | 0.81 | MGLL (0.53) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL15990378 | 0.78 | PDCD1LG2 (0.35) | PDCD1LG2CD274KCNH2 | |
| SCHEMBL27281819 | 0.77 | MGLL (0.56) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL27281807 | 0.77 | MGLL (0.52) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL24841890 | 0.77 | MGLL (0.52) | MGLLPIK3CDCYP2D6SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308123-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | BLACKSMITH MEDICINES, INC. | 2021-07-22 | — | — | US | disclosed |
| WO-2020061375-A1 | ANTIBACTERIAL COMPOUNDS | FORGE THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020037091-A1 | IMIDAZO[4,5-C]QUINOLINE DERIVED NLRP3-MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221796-A1 | ANTIBACTERIAL COMPOUNDS | SPOUT1, MRPL21, NRDC | MGLL 1333/4885PIK3CD 913/4885PDCD1LG2 3980/4885 |
| US-20210308123-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | MGLL 3829/4885PIK3CD 3368/4885PDCD1LG2 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.